Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S246000, C548S245000, C548S133000, C548S131000, C546S272100, C546S209000, C544S367000, C514S364000, C514S361000, C514S340000, C514S326000, C514S252010
Reexamination Certificate
active
06852745
ABSTRACT:
Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 5519143 (1996-05-01), Harris
patent: 5627191 (1997-05-01), Birch et al.
patent: 5760038 (1998-06-01), Murugesan et al.
patent: 689511 (1999-05-01), None
patent: 922698 (1999-06-01), None
patent: WO 9916437 (1999-04-01), None
Bohlender et al., “Synergistic Effects of AT1and ETAReceptor Blockade in a Transgenic, Angiotension II-Dependent, Rat Model”, Hypertension, vol. 35(4), pp. 992-997 (2000).
Chua et al., “Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells”, Biochimica et Biophysica Acta, vol. 1178, pp. 201-206 (1993).
Dhein et al., “Long-Term Effects of the EndothelinAReceptor Antagonist LU 135252 and the Angiotensin-Converting Enzyme Inhibitor Trandolapril on Diabetic Angiopathy and Nephropathy in a Chronic Type I Diabetes Mellitus Rat Model”, J. of Pharmacology and Experimental Therapeutics, vol. 293(2), pp. 351-359 (2000).
Ferrario, C.M., “The Renin-Angiotensin System: Importance in Physiology and Pathology”, J. Cardiovasc. Phamacol., vol. 15(Suppl. 3), pp. S1-S5, (1990).
Gardiner et al., “Haemodynamic effects of Iosartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats”, British J. of Pharmacology, vol. 116, pp. 2237-2244 (1995).
Ikeda et al., “Antihypertensive Effects of a Mixed Endothelin-A- and -B- Receptor Antagonist, J-104132, Were Augmented in the Presence of an ATl-Receptor Antagonist, MK-954”, J. of Cardiovascular Pharmacology, vol. 36(Suppl. 1), pp. S337-S341 (2000).
Imai et al., “Induction of Endothelin-1 Gene by Angiotensin and Vasopressin in Endothelial Cells”, Hypertension, vol. 19, pp. 753-757 (1992).
Inoue et al., “The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes”, Proc. Natl. Acad. Sci. USA, vol. 86, pp. 2863-2867, Apr. 1989.
Massart et al., “Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension”, J. Hypertension, vol. 16, pp. 835-841 (1998).
Yanagisawa et al., “A novel potent vasoconstrictor peptide produced by vascular endothelial cells”, Nature, vol. 332, pp. 411-415 (Mar. 31, 1988).
Beilstein online abstract, Registry No. 537418.
Gu Zhengxiang
Macor John E.
Murugesan Natesan
Tellew John E.
Aulakh Charanjit S.
Bristol--Myers Squibb Company
Davis Stephen B.
Gu Henry H.
LandOfFree
Biphenyl sulfonamides as dual angiotensin endothelin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biphenyl sulfonamides as dual angiotensin endothelin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biphenyl sulfonamides as dual angiotensin endothelin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498704